EUVIMEDEUVIMED entdecken
Crossref

Pluronic F127‐Complexed PEGylated Poly(glutamic acid)‐Cisplatin Nanomedicine for Enhanced Glioblastoma Therapy

Xiaoyu Chang iD, Jiaxue Liu iD, Yunqian Li iD, Wenliang Li iD

Macromolecular Rapid Communications · 2024

DOI: 10.1002/marc.202400662 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Macromolecular Rapid Communications, 2024. Verfasst von Xiaoyu Chang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, the First Hospital of Jilin University, 1 Xinmin Street, Changchun, 130061, P. R. China. Hauptthemen laut MEDLINE: Cisplatin, Glioblastoma, Poloxamer, Polyglutamic Acid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Jilin Province Medical and Health Talent Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma is one of the most aggressive and treatment‐resistant forms of primary brain cancer, posing significant challenges in effective therapy. This study aimed to enhance the effectiveness of glioblastoma therapy by developing a unique nanomedicine composed of Pluronic F127‐complexed PEGylated poly(glutamic acid)‐cisplatin (PLG‐PEG/PF127‐CDDP). PLG‐PEG/PF127‐CDDP demonstrated an optimal size of 133.97 ± 12.60 nm, facilitating efficient cell uptake by GL261 glioma cells. In vitro studies showed significant cytotoxicity against glioma cells with a half‐maximal (50%) inhibitory concentration (IC50) of 12.61 µg mL −1 at 48 h and a 72.53% ± 1.89% reduction in cell invasion. Furthermore, PLG‐PEG/PF127‐CDDP prolonged the circulation half‐life of cisplatin to 9.75 h in vivo, leading to a more than 50% reduction in tumor size on day 16 post‐treatment initiation in a murine model of glioma. The treatment significantly elevated lactate levels in GL261 cells, indicating enhanced metabolic disruption. Therefore, PLG‐PEG/PF127‐CDDP offers a promising approach for glioblastoma therapy due to its effects on improving drug delivery efficiency, therapeutic outcomes, and safety while minimizing systemic side effects. This work underscores the potential of polymer‐based nanomedicines in overcoming the challenges of treating brain tumors, paving the way for future clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinGlioblastomaPoloxamerPolyglutamic AcidPolyethylene GlycolsAntineoplastic AgentsNanomedicineAnimalsMiceHumansCell Line, TumorBrain NeoplasmsDrug Screening Assays, AntitumorCell ProliferationCell SurvivalParticle SizeNanoparticlesDrug Carriers

Stichwörter der Autor:innen

controlled drug deliveryglioblastoma chemotherapypassage of blood‐brain barrierpoly(amino acid) nanomedicinepolymer nanoparticle

Substanzen

CisplatinPoloxamerPolyglutamic AcidPolyethylene GlycolsAntineoplastic AgentsDrug Carriers

Autor:innen und Institutionen

  • Department of Neurosurgery, the First Hospital of Jilin University, 1 Xinmin Street, Changchun, 130061, P. R. China.
  • Jilin Collaborative Innovation Center for Antibody Engineering, Jilin Medical University, 5 Jilin Street, Jilin, 132000, P. R. China.
  • Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun, 130022, P. R. China.

ORCID-Profile: Xiaoyu Chang, Jiaxue Liu, Yunqian Li, Wenliang Li

Förderung

  • Jilin Province Medical and Health Talent Project

Zitieren

APA

Chang, X., Liu, J., Li, Y., & Li, W. (2024). Pluronic F127‐Complexed PEGylated Poly(glutamic acid)‐Cisplatin Nanomedicine for Enhanced Glioblastoma Therapy. Macromolecular Rapid Communications. https://doi.org/10.1002/marc.202400662

Vancouver

Chang X, Liu J, Li Y, Li W. Pluronic F127‐Complexed PEGylated Poly(glutamic acid)‐Cisplatin Nanomedicine for Enhanced Glioblastoma Therapy. Macromolecular Rapid Communications. 2024. doi:10.1002/marc.202400662

BibTeX
@article{Chang2024,
  author = {Chang, Xiaoyu and Liu, Jiaxue and Li, Yunqian and Li, Wenliang},
  title = {Pluronic F127‐Complexed PEGylated Poly(glutamic acid)‐Cisplatin Nanomedicine for Enhanced Glioblastoma Therapy},
  journal = {Macromolecular Rapid Communications},
  year = {2024},
  doi = {10.1002/marc.202400662}
}
Kostenlos starten →